在缺血性心力衰竭和扩展性心肌病中进行过导管左心室恢复
Muhammad Mohid Haroon1, Faizan Ahmad2, Ramsha Ali3
1Ameer-ud-Din Medical College/Lahore General Hospital, Lahore, Pakistan.
概括
过导管左心室恢复 (TLVR) 提供了一种微创的方法来改善心力衰竭的结果. 这一元分析表明,TLVR有效地减少左心室体积,增强排气分数,改善患者的症状.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 心脏衰竭研究研究
背景情况:
- 缺血性心脏病是导致死亡的主要原因,通常导致缺血性心力衰竭 (IHF) 和左心室 (LV) 逆转型.
- 手术 LV 恢复提供好处,但受到侵入性和可变结果的限制.
- 透导管左心室修复 (TLVR) 是LV修复的最少侵入性的替代方案.
研究的目的:
- 综合证据证实了跨导管左心室修复 (TLVR) 在不同设备的疗效.
- 评估TLVR对左心室 (LV) 重塑,功能和临床结果的影响.
- 确定未来对TLVR进行心力衰竭管理的研究领域.
主要方法:
- 按照PRISMA 2020指南进行系统的元分析.
- 搜索了PubMed,Embase,Scopus和Cochrane图书馆的符合条件的研究,直到2025年7月.
- 包括十七个单臂干预和观察性研究,对成人患者进行TLVR.
主要成果:
- TLVR显著降低了 LV 末端透析体积 (LVEDV) (MD -25.94 mL) 和增加了 LV 喷射分数 (LVEF) (+6.69%).
- 纽约心脏协会 (NYHA) 患者类改善 (MD -0.73),表明功能状况更好.
- 虽然Revivent TC和AccuCinch等一些设备显示出一致的好处,但Parachute的结果更为可变. 在KCCQ得分中,整体改善不显著.
结论:
- 这一元分析表明,TLVR始终改善了LV重塑,心脏功能和患者症状.
- 尽管有希望的结果,但高异质性,小研究队列和有限的后续需要进一步调查.
- 大型随机试验对于确定TLVR的长期耐用性,生存益处和最佳患者选择至关重要.
相关概念视频
Cardiomyopathy V: Interprofessional Care
313
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
313
Cardiomyopathy II: Dilated Cardiomyopathy
436
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
436
Heart Failure VI: Adjunct Therapies
235
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
235
Cardiac Catheterization III: Left Heart Catheterization
526
Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
526
Cardiomyopathy III: Hypertrophic Cardiomyopathy
362
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
362


